A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age

Not Applicable

Not yet recruiting

• Conditions: Pneumonia, Bacterial
• Interventions: Biological: Pn-MAPS30plus; Combination Product: PCV20

• Registration Number: NCT07105722
• Lead Sponsor: GlaxoSmithKline

Brief Summary

This clinical study is designed to evaluate an investigational pneumococcal vaccine named Pn-MAPS30plus. The vaccine is designed to stimulate the immune system to produce antibodies against various serotypes of the S. pneumoniae bacteria, potentially aiding the body in fighting infection upon exposure. Pn-MAPS30plus aims to broaden protection by covering more serotypes than currently licensed pneumococcal vaccines. The study's purpose is to determine whether the vaccine is safe, well-tolerated, and effective in inducing immune responses against S. pneumoniae.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-08
• Study First Submitted: 2025-08-04
• Study First Submitted QC: 2025-08-04
• Study First Posted: 2025-08-06
• Last Update Submitted: 2025-08-07
• Study Start: 2025-08-12
• Last Update Posted: 2025-08-12
• Primary Completion: 2026-06-18
• Study Completion: 2026-06-18

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

1. Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
2. Written or witnessed/thumb printed informed consent obtained from the participant prior to performance of any trial-specific procedure.
3. Healthy male and female participants between and including 50 through 64 YOA at the time of Informed consent form (ICF) signature.
4. Female participants of childbearing potential may be enrolled if they practice adequate contraception and have a negative pregnancy test prior to study intervention administration.

Exclusion Criteria

1. History of microbiologically proven Invasive Pneumococcal Disease (IPD) caused by S. pneumoniae within the past 3 years.
2. History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s).
3. Any confirmed or suspected immunosuppressive or immunodeficient condition.
4. Hypersensitivity to latex.
5. Clinical conditions representing a contraindication to intramuscular vaccination, and blood collection.
6. Documented history of Human immunodeficiency virus (HIV)-positive participant.
7. Acute or unstable chronic clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, or metabolic conditions as determined by the investigator.
8. Recurrent history of uncontrolled neurological or any neuroinflammatory disorders.
9. Any behavioural or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with trial participation.
10. History of potential immune-mediated disorders (pIMDs).
11. Any other clinical condition that, might pose additional risk to the participant.
12. Use of any investigational or non-registered product other than the study interventions during the period beginning 30 days before the study intervention administration.
13. History of previous vaccination with any pneumococcal vaccine.
14. Receipt of blood or plasma products or immunoglobulins, from 90 days before study intervention administration, or planned receipt within 30 days of study intervention administration.
15. Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune-modifying treatments at any time up to the end of the trial.
16. Pregnant or lactating female participant.
17. History of chronic alcohol consumption and/or drug abuse, based on investigator judgment.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Pn-MAPS30plus Group	Pn-MAPS30plus	Participants receive a single dose of Pn-MAPS30plus on Day 1.
PCV20 Group	PCV20	Participants receive a single dose of PCV20 on Day 1.

Primary Outcome Measures

Name	Time	Method
Number of Participants with Each Solicited Administration Site (Local) Event	Day 1 (post-vaccination) to Day 7
Number of Participants with Each Solicited Systemic Event	Day 1 (post-vaccination) to Day 7
Number of Participants with Any Unsolicited Adverse Events (AEs)	Day 1 (post-vaccination) to Day 30
Number of Participants with Serious AEs (SAEs), Adverse Events of Special Interest (AESIs) and AEs Leading to Withdrawal	Day 1 up to trial end (Month 6)
Number of Participants with Hematological and Biochemical Laboratory Abnormalities	On Day 8

Trial Locations

Locations (2)

GSK Investigational Site; 🇦🇺 East Melbourne, Victoria, Australia

GSK Investigational site; 🇦🇺 Bayswater, Victoria, Australia